Key facts
- It has raised $58.0M; the latest was Later Stage VC ($10.0M) in May 2024.
- Notable investors include Peregrine Ventures, Marius Nacht, BioGiv Excubator, Cancer Focus Fund, European Innovation Council (Belgium) — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Nectin Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nectin Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nectin Therapeutics
Operator of a biotechnology company intended to treat solid and hematological malignancies. The company develops antibodies that overcome inhibitory pathways deployed by the tumors and help immune cells to effectively destroy cancer cells, enabling medical professionals to improve patient's lives with therapeutic options.
- Sector
- Healthcare
- HQ
- Jerusalem, Israel
- Founded
- 2017
- Employees
- 11
- Website
- nectintx.com/
- Ownership
- Privately Held (backing)
Nectin Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nectin Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nectin Therapeutics in its N-PORT filings yet. We sweep new filings monthly.